Research Associate II, Translation & Exploratory Biology (Histology)

Research Cambridge, MA


What’s in it for you?

We are seeking a highly motivated individual who will be part of the preclinical pharmacology group/Translational and can thrive in a dynamic and collaborative environment.  In this position, you will drive the histology work in our newly developed Translational and Exploratory Biology group. You will be focusing on processing, sectioning, and staining animal and human tissue samples with the result of validating therapeutic potential of different drug targets. You will get to apply your innovative mind to our cutting-edge science and work alongside a motivated team.


What will you be doing?

In order to support our future clinical programs, we are adding a Translational Biology group to our Preclinical department.  This hire will have a significant role in contributing towards exploring biological hypotheses and validating therapeutic potential of different drug targets targeting the TGF-beta superfamily signaling pathway in order to help us achieve our goal of transforming patients’ lives.

  • Collecting, processing, sectioning and embedding different tissues using microtome or cryotome instruments
  • Supporting the other team members in their preclinical studies with end point analyses as described above
  • Tissue staining and evaluation of different proteins using various chromogenic and antibody based approaches such as immunofluorescence, immunohistochemistry and in-situ hybridization
  • Troubleshooting and optimizing RNA in-situ hybridization (RNAscope), tissue staining while automating all tissue processing and staining procedures
  • Imaging by using slide scanner, confocal, and fluorescence microscopy and image analysis by running different image analysis software such as Halo
  • Preliminary data analysis and interpretation
  • Meeting strict project deadlines on assigned projects
  • Presenting data internally in different group meetings
  • Assisting with other Preclinical projects as needed

What are we looking for?

  • S/M.S in biological sciences or related discipline
  • Minimum of 3 years of related histology experience and translational research experience in industry
  • Extensive experience in immunohistochemistry, immunofluorescence staining and microscopic techniques
  • Experience in analyzing microscopic images and histopathological assessments
  • Ability to prioritize responsibilities to meet project deadlines
  • Strong written and oral communication skills, self-motivated, team-oriented and able to work independently
  • Attention to detail supported by excellent time management, organizational and communication skills
  • Ability to approach complex problems creatively and develop innovative solutions


How will you grow with us?

It is truly an exciting time to join the Acceleron team with our robust pipeline and innovative science.  As one of the first to join our newly developed Translational and Exploratory Biology group, you will get a meaningful, hands-on experience where you will learn and expand upon your skills alongside a knowledgeable and supportive team.  If you are looking for a new challenge and the opportunity to contribute to cutting-edge science, then join us!


Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair. Acceleron focuses its commercialization, research, and development efforts in hematologic and pulmonary diseases. In hematology, Acceleron and its global collaboration partner, Bristol Myers Squibb, are co-promoting REBLOZYL® (luspatercept-aamt), the first and only approved erythroid maturation agent, in the United States for the treatment of anemia in certain blood disorders. The Companies are also developing luspatercept for the treatment of chronic anemia in patient populations of MDS, beta-thalassemia, and myelofibrosis. In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension, having recently reported positive topline results of the Phase 2 PULSAR trial. For more information, please visit Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.